Signalife receives $102m lifeline:
This article was originally published in Clinica
Biomedical signal monitoring specialist Signalife has received a welcome financial boost in the shape of a $102m funding from YA Global Investments. The Greenville, South Carolina-based company was issued with an AMEX deficiency letter in June, stating that the company's shareholder equity price had fallen below the minimum threshold for companies with market caps of less than $50m. Signalife has received $2m upfront from the sale of common stock and warrants to YA, and has entered a standby equity distribution agreement with the investment firm that will see the sale of $100m in additional stock over the next three years. As well as repairing the company's stock market position, the funding will also help sales and marketing of its lead product, the Fidelity 100 heart monitor, designed to detect early signs of cardiovascular disease.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.